Phase 3 REZILIENT3 data: zipalertinib plus chemotherapy significantly extended progression-free survival in first-line EGFR exon 20 insertion-positive NSCLC.
#Biotech #Biotechnology #Oncology
Disclaimer: This is NOT a financial advice.
Phase 3 REZILIENT3 data: zipalertinib plus chemotherapy significantly extended progression-free survival in first-line EGFR exon 20 insertion-positive NSCLC. #Biotech #Biotechnology #Oncology Disclaimer: This is NOT a financial advice.
0 vue
Publié le 21/09/2026 03:31
0:17
Phase 3 REZILIENT3 data: zipalertinib plus chemotherapy significantly extended progression-free survival in first-line EGFR exon 20 insertion-positive NSCLC.
#Biotech #Biotechnology #Oncology
Disclaimer: This is NOT a financial advice.
0 commentaire
?